Published in J Am Soc Nephrol on August 01, 2013
Complement System Part II: Role in Immunity. Front Immunol (2015) 1.31
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest (2015) 1.08
Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol (2016) 0.97
Complement in disease: a defence system turning offensive. Nat Rev Nephrol (2016) 0.97
Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol (2015) 0.96
Update on C3 glomerulopathy. Nephrol Dial Transplant (2014) 0.94
Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment. World J Transplant (2015) 0.90
Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology (2015) 0.90
Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases. Front Immunol (2016) 0.88
Applying complement therapeutics to rare diseases. Clin Immunol (2015) 0.87
The emerging role of complement inhibitors in transplantation. Kidney Int (2015) 0.86
Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int (2015) 0.84
New milestones ahead in complement-targeted therapy. Semin Immunol (2016) 0.81
From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology (2016) 0.80
Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol (2015) 0.80
A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. J Am Soc Nephrol (2015) 0.76
Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol (2016) 0.76
A previously unrecognized role of C3a in proteinuric progressive nephropathy. Sci Rep (2016) 0.75
New classification of membranoproliferative glomerulonephritis: a good start but a long way to go. Kidney Res Clin Pract (2014) 0.75
Complement related kidney diseases: Recurrence after transplantation. World J Transplant (2016) 0.75
Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol (2017) 0.75
Targeting the complement cascade: novel treatments coming down the pike. Kidney Int (2016) 0.75
Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets. J Leukoc Biol (2016) 0.75
Dysregulation of mCD46 and sCD46 contribute to the pathogenesis of bullous pemphigoid. Sci Rep (2017) 0.75
Current concepts in C3 glomerulopathy. Indian J Nephrol (2014) 0.75
Complement in Lupus Nephritis: New Perspectives. Kidney Dis (Basel) (2015) 0.75
Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends Immunol (2017) 0.75
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 4.67
Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet (2002) 4.22
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int (2011) 2.61
Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol (2011) 2.32
Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med (1987) 2.28
Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest (2010) 2.18
Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol (1998) 1.96
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest (2008) 1.94
Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol (2012) 1.70
Dense deposit disease. Mol Immunol (2011) 1.31
Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol (2005) 1.29
Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int (2010) 1.25
Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1. J Exp Med (1984) 1.23
Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol (2011) 1.13
Mapping epitopes for 20 monoclonal antibodies to CR1. Clin Exp Immunol (1998) 1.12
Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase. Mol Immunol (2009) 1.09
Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens (2013) 1.07
The C3b/C4b receptor is recognized by the Knops, McCoy, Swain-langley, and York blood group antisera. J Exp Med (1991) 0.98
A descriptive study of individuals with membranoproliferative glomerulonephritis. Nephrol Nurs J (2007) 0.94
The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev Cardiovasc Ther (2006) 0.92
Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation (2004) 0.90
The human C3b receptor (CR1). Adv Nephrol Necker Hosp (1989) 0.88
Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation (2007) 0.85
Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Am Heart J (2004) 0.85
Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21). Immunodefic Rev (1990) 0.85
Factor I-dependent inactivation of human complement C4b of the classical pathway by C3b/C4b receptor (CR1, CD35) and membrane cofactor protein (MCP, CD46). J Biochem (1992) 0.83
Abnormal immune complex processing and spontaneous glomerulonephritis in complement factor H-deficient mice with human complement receptor 1 on erythrocytes. J Immunol (2010) 0.83
A hemolytic method for the measurement of nephritic factor. J Immunol Methods (2007) 0.82
Complement receptor type 1 (CR1, CD35) expression on peripheral T lymphocytes: both CD4- and CD8-positive cells express CR1. Complement Inflamm (1991) 0.79
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A (2005) 13.44
Syndromes of thrombotic microangiopathy. N Engl J Med (2014) 5.41
Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 3.85
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis (2011) 3.81
Forty-six genes causing nonsyndromic hearing impairment: which ones should be analyzed in DNA diagnostics? Mutat Res (2008) 3.76
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int (2009) 3.12
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet (2005) 2.63
Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int (2011) 2.61
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat (2010) 2.44
SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes. Proc Natl Acad Sci U S A (2004) 2.41
Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int (2012) 2.28
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol (2005) 1.96
An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol (2014) 1.95
Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation (2008) 1.92
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol (2011) 1.92
A forward genetics screen in mice identifies recessive deafness traits and reveals that pejvakin is essential for outer hair cell function. J Neurosci (2007) 1.90
Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest (2010) 1.87
Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int (2012) 1.81
Prestin, a cochlear motor protein, is defective in non-syndromic hearing loss. Hum Mol Genet (2003) 1.80
Prevalence and evolutionary origins of the del(GJB6-D13S1830) mutation in the DFNB1 locus in hearing-impaired subjects: a multicenter study. Am J Hum Genet (2003) 1.79
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int (2013) 1.79
Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.79
Branchio-oto-renal syndrome: the mutation spectrum in EYA1 and its phenotypic consequences. Hum Mutat (2004) 1.77
Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol (2012) 1.70
Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum Mutat (2003) 1.67
Advancing genetic testing for deafness with genomic technology. J Med Genet (2013) 1.66
Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice. Am J Hum Genet (2008) 1.65
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int (2011) 1.62
Transcriptional control of SLC26A4 is involved in Pendred syndrome and nonsyndromic enlargement of vestibular aqueduct (DFNB4). Am J Hum Genet (2007) 1.59
Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol (2011) 1.58
Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis (2010) 1.57
Postinfectious glomerulonephritis in the elderly. J Am Soc Nephrol (2010) 1.57
Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure. Nephrol Dial Transplant (2010) 1.57
Frequency of Usher syndrome in two pediatric populations: Implications for genetic screening of deaf and hard of hearing children. Genet Med (2010) 1.56
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis (2005) 1.54
Transcription factor SIX5 is mutated in patients with branchio-oto-renal syndrome. Am J Hum Genet (2007) 1.52
New treatment options for lymphangioma in infants and children. Ann Otol Rhinol Laryngol (2002) 1.50
Audioprofile-directed screening identifies novel mutations in KCNQ4 causing hearing loss at the DFNA2 locus. Genet Med (2008) 1.49
Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates. Hum Vaccin Immunother (2012) 1.46
Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol (2010) 1.45
Chronic thrombotic microangiopathy secondary to chemotherapy for urothelial carcinoma in a patient with a history of Wegener granulomatosis. Am J Kidney Dis (2011) 1.45
Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol (2010) 1.42
Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol (2005) 1.41
No evidence for association between the renin-angiotensin-aldosterone system and otosclerosis in a large Belgian-Dutch population. Otol Neurotol (2009) 1.40
Function and expression pattern of nonsyndromic deafness genes. Curr Mol Med (2009) 1.40
Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol (2008) 1.39
Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol (2011) 1.38
Mutations in a novel gene, TMIE, are associated with hearing loss linked to the DFNB6 locus. Am J Hum Genet (2002) 1.37
Mutations of the RDX gene cause nonsyndromic hearing loss at the DFNB24 locus. Hum Mutat (2007) 1.37
Deafness in the genomics era. Hear Res (2011) 1.37
Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans. Am J Hum Genet (2009) 1.37
Loss-of-function mutations of ILDR1 cause autosomal-recessive hearing impairment DFNB42. Am J Hum Genet (2011) 1.37
Sensorineural deafness and male infertility: a contiguous gene deletion syndrome. J Med Genet (2006) 1.36
Branchio-oto-renal syndrome (BOR): novel mutations in the EYA1 gene, and a review of the mutational genetics of BOR. Hum Mutat (2008) 1.35
Discovery of a spontaneous genetic mouse model of preeclampsia. Hypertension (2002) 1.35
Branchio-oto-renal syndrome. Am J Med Genet A (2007) 1.34
Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. Arterioscler Thromb Vasc Biol (2004) 1.33
Gipc3 mutations associated with audiogenic seizures and sensorineural hearing loss in mouse and human. Nat Commun (2011) 1.33
Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2013) 1.32
Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. Am J Med Genet A (2004) 1.32
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. Clin Trials (2005) 1.31
A claudin-9-based ion permeability barrier is essential for hearing. PLoS Genet (2009) 1.29
Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol (2011) 1.29
Inactivation of NADPH oxidase organizer 1 results in severe imbalance. Curr Biol (2006) 1.27
Syndromes of thrombotic microangiopathy. N Engl J Med (2014) 1.25
Advances in molecular and cellular therapies for hearing loss. Mol Ther (2007) 1.25
Causes of facial swelling in pediatric patients: correlation of clinical and radiologic findings. Radiographics (2006) 1.25
Genotype-phenotype correlations for SLC26A4-related deafness. Hum Genet (2007) 1.24
Digital pathology evaluation in the multicenter Nephrotic Syndrome Study Network (NEPTUNE). Clin J Am Soc Nephrol (2013) 1.24
C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis (2013) 1.24
Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int (2010) 1.24
Mutations in the WFS1 gene that cause low-frequency sensorineural hearing loss are small non-inactivating mutations. Hum Genet (2002) 1.23
Genetics: advances in genetic testing for deafness. Curr Opin Pediatr (2012) 1.23
Recent advances in the molecular genetics of epilepsy. J Med Genet (2013) 1.21
How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood (2012) 1.19
Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis (2012) 1.19
Human male infertility caused by mutations in the CATSPER1 channel protein. Am J Hum Genet (2009) 1.19
Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol (2013) 1.19
Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood (2013) 1.19
SIX1 mutation screening in 247 branchio-oto-renal syndrome families: a recurrent missense mutation associated with BOR. Hum Mutat (2008) 1.17